Faruqi and Faruqui, LLP Logo
Share this page

Cases: Antitrust Litigation

< 1 2 3
Page 3 of 3 (46 Items)
05
Jun
2006

In re Metoprolol Succinate Direct Purchaser Antitrust Litigation, No. 06-52 (D. Del.)

In the Toprol case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of AstraZeneca’s branded drug Toprol XL (extended-release metoprolol succinate).  The case alleges that AstraZeneca fraudulently procured two patents and filed multiple baseless patent infringement lawsuits using those patents, solely in an effort... READ MORE

27
Apr
2006

King Drug Company of Florence, Inc., et al. v. Cephalon, Inc., et al., No. 06-1797 (E.D. Pa.)

In this case, nicknamed Provigil, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Cephalon’s (now Teva’s) branded wakefulness drug, Provigil (modafinil).  The case alleges that that the brand manufacturer, Cephalon, conspired with 4 generic competitors not to launch their generic versions of... READ MORE

28
Dec
2005

Babyage.com, Inc., et al. v. Toys "R" Us, Inc., No. 05-6792 (E.D. Pa.)

In Babyage.com, Inc., et al. v. Toys “R” Us, Inc., et al., Faruqi & Faruqi, LLP represented three internet retailers of baby products, who challenged a dominant retailer’s anticompetitive scheme, in concert with co-conspirator manufacturers, to impose and enforce resale price maintenance in violation of §§ 1 and 2 of... READ MORE

11
Aug
2005

In re Tricor Antitrust Litigation, No. 05-360 (D. Del.)

Faruqi & Faruqi represented PacifiCare, and other large third-party payors challenging the conduct of Abbott Laboratories and Laboratories Fournier in suppressing generic drug competition, in violation of §§ 1 and 2 of the Sherman Act. The Tricor case settled for undisclosed amount in 2010.

30
Jun
2005

In re Ready-Mixed Concrete Antitrust Litigation, No. 05-979 (S.D. Ind.)

Faruqi & Faruqi represented a class of direct purchasers of ready-mixed concrete challenging conspiracy to fix prices in the Indianapolis market, in violation of § 1 of the Sherman Act.  This price fixing case settled in 2009 in excess of $40 million.

01
Mar
2005

In re Hypodermic Products Antitrust Litigation, No. 05-1602 (D.N.J.)

In the In re Hypodermic Products Antitrust Litigation, Faruqi & Faruqi, LLP represents a proposed class of direct purchasers of hypodermic products (needles, syringes, blood collection devices, catheters, etc.), who are challenging a bundled pricing and exclusionary contracting scheme by Becton Dickinson and Company.  Following appellate practice with a competing... READ MORE

< 1 2 3
Page 3 of 3 (46 Items)